Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Protara Therapeutics announced its second quarter 2026 financial results and provided updates on its clinical pipeline, including enrollment progress in its ADVANCED-2 and STARBORN-1 trials, and the redesign of the ADVANCED-3 trial to broaden data collection in non-muscle invasive bladder cancer. The company anticipates submitting a Biologics Licen…